Abstract

Mucolipidosis type II (MLII) is a severe multi-systemic genetic disorder caused by missorting of lysosomal proteins and the subsequent lysosomal storage of undegraded macromolecules. Although affected children develop disabling skeletal abnormalities, their pathogenesis is not understood. Here we report that MLII knock-in mice, recapitulating the human storage disease, are runted with accompanying growth plate widening, low trabecular bone mass and cortical porosity. Intralysosomal deficiency of numerous acid hydrolases results in accumulation of storage material in chondrocytes and osteoblasts, and impaired bone formation. In osteoclasts, no morphological or functional abnormalities are detected whereas osteoclastogenesis is dramatically increased in MLII mice. The high number of osteoclasts in MLII is associated with enhanced osteoblastic expression of the pro-osteoclastogenic cytokine interleukin-6, and pharmacological inhibition of bone resorption prevented the osteoporotic phenotype of MLII mice. Our findings show that progressive bone loss in MLII is due to the presence of dysfunctional osteoblasts combined with excessive osteoclastogenesis. They further underscore the importance of a deep skeletal phenotyping approach for other lysosomal diseases in which bone loss is a prominent feature.

Highlights

  • Mucolipidosis type II (MLII) is a severe multi-systemic genetic disorder caused by missorting of lysosomal proteins and the subsequent lysosomal storage of undegraded macromolecules

  • MLII mice are reduced in size and display osteopenia To analyse the skeletal phenotype of MLII mice we first stained skeletons of one week‐old wild‐type and MLII littermates with alcian blue and alizarin red

  • This was confirmed by contact radiography of 4‐ and 12‐week‐old mice, where we found that lumbar spine and femur length were significantly reduced in MLII mice compared to wild‐type littermates (Fig 1B and C)

Read more

Summary

Introduction

Mucolipidosis type II (MLII) is a severe multi-systemic genetic disorder caused by missorting of lysosomal proteins and the subsequent lysosomal storage of undegraded macromolecules. Our findings show that progressive bone loss in MLII is due to the presence of dysfunctional osteoblasts combined with excessive osteoclastogenesis They further underscore the importance of a deep skeletal phenotyping approach for other lysosomal diseases in which bone loss is a prominent feature. Www.embomolmed.org dysmorphism, psychomotor retardation, cardiorespiratory defects and early death between 5 and 8 years of age (Braulke et al, 2013; Cathey et al, 2010; Spranger & Wiedemann, 1970) The majority of these severely affected MLII patients have nonsense, frameshift or splice site alterations in GNPTAB. We show that increased formation of intact osteoclasts, combined with decreased activity of bone‐forming osteoblasts, is responsible for low bone mass in MLII mice, and that this phenotype can be corrected by anti‐resorptive bisphosphonate treatment

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call